Cited by 236Acute Myeloid Leukemia ResearchMultiple and Secondary Primary CancersRetinoids in leukemia and cellular processes

The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.

Therapy-related leukemia and myelodysplasia: susceptibility and incidence

Open access

Leone, G., Pagano, L., Ben-Yehuda, D., Voso, M. T.·2007·Haematologica

DOI 10.3324/haematol.11034

Open this paper in CoChat — free account Open PDF

Abstract

Therapy-related myelodysplastic syndrome/acute myeloid leukemia (t-MDS/AML) is an increasingly recognized treatment complication in patients treated with radiotherapy or chemotherapy for previous hematologic malignancies or solid tumors. Distinct clinical entities have been described according to the primary treatment, corresponding to defined genetic lesions. Chromosome 7 and/or 5 losses or deletions are typical of alkylating agent-induced AML, while development of t-AML with balanced translocations involving chromosome bands 11q23 and 21q22 has been related to previous therapy with drugs targeting DNA-topoisomerase II. In addition, antimetabolites, and in particular the immunosuppressant azathioprine, have been shown to induce defective DNA-mismatch repair. This could promote survival of misrepaired cells giving rise to the leukemic clone. Individual predisposing factors, including polymorphisms in detoxification and DNA repair enzymes have been identified. Their combination may significantly increase the risk of t-MDS/AML. Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy. Patients with Hodgkin's and non-Hodgkin's lymphoma are at highest risk when total body irradiation followed by autologous stem cell transplantation is used as rescue or consolidation therapy. The addition of granulocyte-colony-stimulating factor and radiotherapy plays a significant role in t-AML following treatment of children with acute lymphoblastic leukemia. In non-hematologic malignancies, treatment for breast cancer and germ-cell tumors has been associated with a 1-5% lifetime risk of both lymphoid as well as myeloid leukemia. In all cases the risk of t-MDS/AML drops sharply by 10 years after treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3324/haematol.11034

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Annual Report to the Nation on the Status of Cancer, 1975–2002, Featuring Population-Based Trends in Cancer Treatment
Edwards, B. K., Brown, M. L., Wingo, P. A., Howe, H. L., Ward, E., Ries, L. A. G., Schrag, D., Jamison, P. M., Jemal, A., Wu, X. C., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji289 · Cited by 955
Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia
Harrison, C. N., Campbell, P. J., Buck, G. A. N., Wheatley, K., East, C. L., Bareford, D., Wilkins, B. S., van der Walt, J. D., Reilly, J. T., Grigg, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043800 · Cited by 921
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series
Smith, S. M., Beau, M. M. L., Huo, D., Karrison, T. G., Sobecks, R. M., Anastasi, J., Vardiman, J. W., Rowley, J. D., & Larson, R. A. (2003) · Blood · doi:10.1182/blood-2002-11-3343 · Cited by 681
Hematotoxicity in Workers Exposed to Low Levels of Benzene
Qing Lan, B., Zhang, L., Li, G., Vermeulen, R. C. H., Weinberg, R. S., Dosemeci, M., Rappaport, S. M., Shen, M., Alter, B. P., Wu, Y., et al. (2004) · Science · doi:10.1126/science.1102443 · Cited by 651
Environment and Cancer: Who Are Susceptible?
Perera, F. P. (1997) · Science · doi:10.1126/science.278.5340.1068 · Cited by 638
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
Finazzi, G. (2004) · Blood · doi:10.1182/blood-2004-09-3426 · Cited by 433
Pharmacogenomics, Regulation and Signaling Pathways of Phase I and II Drug Metabolizing Enzymes
Rushmore, T. H., & Kong, A.-N. T. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337171 · Cited by 425
Secondary leukemias induced by topoisomerase-targeted drugs
Felix, C. A. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00139-0 · Cited by 416
Acute Myeloid Leukemia and Myelodysplastic Syndromes Following Essential Thrombocythemia Treated With Hydroxyurea: High Proportion of Cases With 17p Deletion
Sterkers, Y., Preudhomme, C., Laï, J., Demory, J., Caulier, M. T., Wattel, E., Bordessoule, D., Bauters, F., & Fenaux, P. (1998) · Blood · doi:10.1182/blood.v91.2.616 · Cited by 369
Homologous repair of DNA damage and tumorigenesis:the BRCA connection
Jasin, M. (2002) · Oncogene · doi:10.1038/sj.onc.1206176 · Cited by 363
Association of CYP 3 A 4 genotype with treatment-related leukemia
Felix, C. A., Walker, A. H., Lange, B. J., Williams, T. M., Winick, N. J., Cheung, N. V., Lovett, B. D., Nowell̀, P. C., Blair, I. A., & Rebbeck, T. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13176 · Cited by 310
Prevalence of the Inactivating 609C→T Polymorphism in the NAD(P)H:Quinone Oxidoreductase (NQO1) Gene in Patients With Primary and Therapy-Related Myeloid Leukemia
Larson, R. A., Wang, Y., Banerjee, M., Wiemels, J. L., Hartford, C. M., Beau, M. M. L., & Smith, M. T. (1999) · Blood · doi:10.1182/blood.v94.2.803 · Cited by 304
Acute Myeloid Leukemia and Myelodysplastic Syndrome After Doxorubicin-Cyclophosphamide Adjuvant Therapy for Operable Breast Cancer: The National Surgical Adjuvant Breast and Bowel Project Experience
Smith, R. E., Bryant, J., DeCillis, A. P., & Anderson, S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.114 · Cited by 299
Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy
Hershman, D. L., Neugut, A. I., Jacobson, J. S., Wang, J., Tsai, W., McBride, R. B., Bennett, C. L., & Grann, V. R. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk028 · Cited by 277
Polymorphism in glutathione S -transferase P1 is associated with susceptibility to chemotherapy-induced leukemia
Allan, J. M., Wild, C. P., Rollinson, S. J., Willett, E. V., Moorman, A. V., Dovey, G. J., Roddam, P. L., Roman, E., Cartwright, R. A., & Morgan, G. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191211198 · Cited by 268
Treatment-Associated Leukemia Following Testicular Cancer
Travis, L. B. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.14.1165 · Cited by 256
Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia
Pedersen-Bjergaard, J., Andersen, M. K., Christiansen, D. H., & Nerlov, C. (2002) · Blood · doi:10.1182/blood.v99.6.1909 · Cited by 243
Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin’s Lymphoma Patients
Armitage, J. O., Carbone, P. P., Connors, J. M., Levine, A. M., Bennett, J. M., & Kroll, S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.113 · Cited by 224
Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Société Française d’Oncologie Pédiatrique
Deley, M. L., Leblanc, T. M., Shamsaldin, A., Raquin, M., Lacour, B., Sommelet, D., Chompret, A., Cayuela, J., Bayle, C., Bernheim, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.100 · Cited by 213
Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients
Gangat, N., Wolanskyj, A. P., McClure, R. F., Li, C.-Y., Schwager, S. M., Wu, W., & Tefferi, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404500 · Cited by 206
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study
Metayer, C. (2002) · Blood · doi:10.1182/blood-2002-04-1261 · Cited by 202
Structure-activity relationships and thermal stability of human glutathione transferase P1-1 governed by the H-site residue 105
Johansson, A.-S., Stenberg, G., Widersten, M., & Mannervik, B. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1708 · Cited by 189
Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Trials of Adjuvant Epirubicin for Early Breast Cancer: Correlation With Doses of Epirubicin and Cyclophosphamide
Praga, C., Bergh, J. C. S., Bliss, J. M., Bonneterre, J. M., Cesana, B. M., Coombes, R. C., Fargeot, P., Folin, A., Fumoleau, P., Giuliani, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.029 · Cited by 187
Increased transcriptional activity of the CYP3A4*1B promoter variant
Amirimani, B., Ning, B., Deitz, A. C., Weber, B. L., Kadlubar, F. F., & Rebbeck, T. R. (2003) · Environmental and Molecular Mutagenesis · doi:10.1002/em.10199 · Cited by 183
Thiopurines, DNA damage, DNA repair and therapy-related cancer
Karran, P. (2006) · British Medical Bulletin · doi:10.1093/bmb/ldl020 · Cited by 182
Therapy-Related Myeloid Leukemias Are Observed in Patients With Chronic Lymphocytic Leukemia After Treatment With Fludarabine and Chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011
Morrison, V. A., Rai, K. R., Peterson, B. L., Kolitz, J. E., Elias, L., Appelbaum, F. R., Hines, J., Shepherd, L. E., Larson, R. A., & Schiffer, C. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.128 · Cited by 176
Risk of Second Malignancy After Non-Hodgkin's Lymphoma: A British Cohort Study
Mudie, N. Y., Swerdlow, A. J., Higgins, C. D., Smith, P., Qiao, Z., Hancock, B. W., Hoskin, P., & Linch, D. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2200 · Cited by 172
Polymorphisms in Genes Involved in Homologous Recombination Repair Interact to Increase the Risk of Developing Acute Myeloid Leukemia
Seedhouse, C., Faulkner, R. D., Ashraf, N., Das-Gupta, E. P., & Russell, N. H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0372 · Cited by 164
Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma
Barlogie, B., Tricot, G. J. K., van Rhee, F., Angtuaco, E., Walker, R., Epstein, J., Shaughnessy, J. D., Jagannath, S., Bolejack, V., Gurley, J., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06271.x · Cited by 162
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab
Bennett, J. M. (2005) · Blood · doi:10.1182/blood-2004-12-4690 · Cited by 160
Secondary Myeloid Leukemia and Myelodysplastic Syndromes in Patients Treated for Hodgkin’s Disease: A Report From the German Hodgkin’s Lymphoma Study Group
Josting, A., Wiedenmann, S., Franklin, J. G., May, M., Sieber, M., Wolf, J., Engert, A., & Diehl, V. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.160 · Cited by 159
GlutathioneS-Transferase Polymorphisms and Outcome of Chemotherapy in Childhood Acute Myeloid Leukemia
Davies, S. M., Robison, L. L., Buckley, J. D., Tjoa, T., Woods, W. G., Radloff, G. A., Ross, J. A., & Perentesis, J. P. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1279 · Cited by 151
Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment
Relling, M. V., Boyett, J. M., Blanco, J. G., Raimondi, S. C., Behm, F. G., Sandlund, J. T., Rivera, G. K., Kun, L. E., Evans, W. E., & Pui, C. (2003) · Blood · doi:10.1182/blood-2002-08-2405 · Cited by 151
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients
André, M. P. E. (2003) · Blood · doi:10.1182/blood-2003-04-1124 · Cited by 151
Anthracyclines, Mitoxantrone, Radiotherapy, and Granulocyte Colony-Stimulating Factor: Risk Factors for Leukemia and Myelodysplastic Syndrome After Breast Cancer
Deley, M. L., Suzan, F., Cutuli, B., Delaloge, S., Shamsaldin, A., Linassier, C., Clisant, S., de Vathaire, F., Fenaux, P., & Hill, C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9048 · Cited by 150
Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children
Smith, M. T., Wang, Y., Skibola, C. F., Slater, D. J., Nigro, L. L., Nowell̀, P. C., Lange, B. J., & Felix, C. A. (2002) · Blood · doi:10.1182/blood-2001-12-0264 · Cited by 141
Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia
Kishi, S., Yang, W., Boureau, B., Morand, S. C., Das, S., Chen, P., Cook, E. H., Rosner, G. L., Schuetz, E. G., Pui, C., et al. (2003) · Blood · doi:10.1182/blood-2003-06-2105 · Cited by 130
Moderate Increase of Secondary Hematologic Malignancies After Myeloablative Radiochemotherapy and Autologous Stem-Cell Transplantation in Patients With Indolent Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group
Lenz, G., Dreyling, M. H., Schiegnitz, E., Haferlach, T., Hasford, J., Unterhalt, M., & Hiddemann, W. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.016 · Cited by 125
Therapy-related myelodysplastic syndrome–acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem
Latagliata, R., Petti, M. C., Fenu, S., Mancini, M., Spiriti, M. A. A., Breccia, M., Brunetti, G. A., Avvisati, G., Lo‐Coco, F., & Mandelli, F. (2002) · Blood · doi:10.1182/blood.v99.3.822 · Cited by 123
Negative prognostic value of glutathione S-transferase(GSTM1 and GSTT1) deletions in adult acute myeloid leukemia
Voso, M. T., D’Alò, F., Putzulu, R., Mele, L., Scardocci, A., Chiusolo, P., Latagliata, R., Lo‐Coco, F., Rutella, S., Pagano, L., et al. (2002) · Blood · doi:10.1182/blood.v100.8.2703 · Cited by 123
Self-citation
Breast cancer and acute leukemia: Report of 24 cases and review of the literature
Rosner, F., Carey, R. W., & Zarrabi, M. H. (1978) · American Journal of Hematology · doi:10.1002/ajh.2830040207 · Cited by 109
Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies
Blanco, J. G., Edick, M. J., Hancock, M. L., Winick, N. J., Dervieux, T., Amylon, M. D., Bash, R. O., Behm, F. G., Camitta, B. M., Pui, C., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200211000-00004 · Cited by 100
Second malignancies in children with neuroblastoma after combined treatment with 131I‐metaiodobenzylguanidine
Garaventa, A., Gambini, C., Villavecchia, G., Cataldo, A. D., Bertolazzi, L., Pizzitola, M. R., Bernardi, B. D., & Haupt, R. (2003) · Cancer · doi:10.1002/cncr.11167 · Cited by 95
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha
McLaughlin, P. J., Estey, E. H., Glassman, A. B., Romaguera, J. E., Samaniego, F., Ayala, A. B., Hayes, K. J., Maddox, A. M., Preti, H. A., & Hagemeister, F. B. (2005) · Blood · doi:10.1182/blood-2004-08-3035 · Cited by 90
Cytochrome P450 and Anticancer Drugs
Fujita, K. (2005) · Current Drug Metabolism · doi:10.2174/138920006774832587 · Cited by 90
Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients
Rund, D. G., Krichevsky, S., Cohen, S. B., Goldschmidt, N., Kedmi, M., Malik, E., Gural, A., Shafran‐Tikva, S., Ben‐Neriah, S., & Ben‐Yehuda, D. (2005) · Leukemia · doi:10.1038/sj.leu.2403947 · Cited by 80
Self-citation
Acute Myeloid Leukemia Following Hodgkin Lymphoma: A Population-Based Study of 35 511 Patients
Schonfeld, S. J., Gilbert, E. S., Dores, G. M., Lynch, C. F., Hodgson, D. C., Hall, P. N., Storm, H. H., Andersen, A., Pukkala, ., Holowaty, E. J., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj017 · Cited by 80
Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation
Barnard, D., Lange, B., Alonzo, T. A., Buckley, J. D., Kobrinsky, J. N., Gold, S., Neudorf, S. M. L., Sanders, J. E., Burden, L., & Woods, W. G. (2002) · Blood · doi:10.1182/blood.v100.2.427 · Cited by 78
Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience
Lobe, I., Huguet, F., Vekhoff, A., Desablens, B., Bordessoule, D., Mounier, C., Ferrant, A., Sanz, M. Á., Fey, M. F., Chomienne, C., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403034 · Cited by 77
An Intron Splice Acceptor Polymorphism in hMSH2 and Risk of Leukemia after Treatment with Chemotherapeutic Alkylating Agents
Worrillow, L. J., Travis, L. B., Smith, A. G., Rollinson, S. J., Smith, A. J. P., Wild, C. P., Holowaty, E. J., Kohler, B., Wiklund, T. A., Pukkala, ., et al. (2003) · PubMed · doi:10.25405/ncl.34299504 · Cited by 76
Therapy-related myelodysplastic syndromes.
Dj, P., & Hp, K. (1996) · PubMed · Cited by 76
Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: effects on levels of sister chromatid exchanges and chromosomal aberrations
Tuimala, J., Szekely, G., Wikman, H., Järventaus, H., Hirvonen, A., Gundy, S., & Norppa, H. (2004) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.05.009 · Cited by 74
Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia
Pui, C., Pei, D., Sandlund, J. T., Campana, D., Ribeiro, R. C., Razzouk, B. I., Rubnitz, J. E., Howard, S. C., Hijiya, N., Jeha, S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.0033 · Cited by 71
Acute Myelogenous Leukemia After Treatment for Malignant Germ Cell Tumors in Children
Schneider, D. T., Hilgenfeld, E., Schwabe, D., Behnisch, W., Zoubek, A., Wessalowski, R., & Göbel, U. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3226 · Cited by 67
The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino, E., Anselmo, A. P., Klersy, C., Santoro, M., Orlandi, E. M., PAGNUCCO, G., Lunghi, F., Maurizi-Enrici, R., Baroni, C. D., Lazzarino, M., et al. (1998) · PubMed · Cited by 66
Therapy-related myeloid leukaemia: A model for leukemogenesis in humans
Larson, R. A., & Beau, M. M. L. (2005) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2005.03.023 · Cited by 66
Fifteen‐year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high‐dose irradiation
Delwail, V., Jaïs, J., Colonna, P., & Andrieu, J. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03564.x · Cited by 66
Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia
Pagano, L., Pulsoni, A., Tosti, M. E., Avvisati, G., Mele, L., Mele, A., Martino, B., Visani, G., Cerri, R., Bona, E. D., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02527.x · Cited by 65
Self-citation
Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1
Haase, D. T., Binder, C. R., Bünger, J., Fonatsch, C., Streubel, B., Schnittger, S., Griesinger, F., Westphal, G., Schoch, C., Knopp, A., et al. (2002) · Leukemia Research · doi:10.1016/s0145-2126(01)00124-2 · Cited by 60
Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?
Hake, C. R., Graubert, T. A., & Fenske, T. S. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705547 · Cited by 58
Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia
Sasai, Y., Horiike, S., Misawa, S., Kaneko, H., Kobayashi, M., Fujii, H., Kashima, K., & Taniwaki, M. (1999) · Leukemia Research · doi:10.1016/s0145-2126(99)00119-8 · Cited by 57
Leukemia following breast cancer: an international population-based study of 376,825 women
Howard, R. A., Gilbert, E. S., Chen, B. E., Hall, P. N., Storm, H. H., Pukkala, ., Langmark, F., Kaijser, M., Andersson, M., Joensuu, H., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9460-0 · Cited by 47
Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t‐AML/MDS
Fern, L. A., Pallis, M., Carter, G. I., Seedhouse, C., Russell, N. H., & Byrne, J. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05006.x · Cited by 37
Hematotoxicity in Workers Exposed to Low Levels of Benzene
Lan, Q. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/bg6f-8m46 · Cited by 31
Secondary Leukemias in Refractory Germ Cell Tumor Patients Undergoing Autologous Stem-Cell Transplantation Using High-Dose Etoposide
Houck, W., Abonour, R., Vance, G. H., & Einhorn, L. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.054 · Cited by 29
Prevalence of the Inactivating 609C→T Polymorphism in the NAD(P)H:Quinone Oxidoreductase (NQO1) Gene in Patients With Primary and Therapy-Related Myeloid Leukemia
Larson, R. A., Wang, Y., Banerjee, M., et al. (1999) · Blood · doi:10.1182/blood.v94.2.803.414k44_803_807 · Cited by 27
Leukemia incidence following primary breast carcinoma treatment
Kaplan, H. G., Malmgren, J. A., & Atwood, M. K. (2004) · Cancer · doi:10.1002/cncr.20475 · Cited by 26
Repeated Sequences in CASPASE-5 and FANCD2 but not NF1 Are Targets for Mutation in Microsatellite-Unstable Acute Leukemia/Myelodysplastic Syndrome
Offman, J., Gascoigne, K. E., Bristow, F., Macpherson, P., Bignami, M., Casorelli, I., Leone, G. G. M., Pagano, L., Sica, S., Halil, O., et al. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0182 · Cited by 24
Self-citation
High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia
Milligan, D. W., Kochethu, G., Dearden, C. E., Matutes, E., MacConkey, C., & Catovsky, D. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.05982.x · Cited by 23
Acute myeloid leukemia in patients previously diagnosed with breast cancer: Experience of the GIMEMA group
Pagano, L., Pulsoni, A., Mele, L., Tosti, M. E., Cerri, R., Visani, G., Melillo, L. M. A., Candoni, A., Clavio, M., Nosari, A., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008318816244 · Cited by 23
Self-citation
Acute Myeloid Leukemia and Myelodysplastic Syndromes Following Essential Thrombocythemia Treated With Hydroxyurea: High Proportion of Cases With 17p Deletion
Sterkers, Y., Preudhomme, C., Laï, J., et al. (1998) · Blood · doi:10.1182/blood.v91.2.616.616_616_622 · Cited by 23
Ionizing radiation and leukaemia: more questions than answers
Wright, E. G. (2005) · Hematological Oncology · doi:10.1002/hon.763 · Cited by 21
Secondary haematological neoplasm after treatment of adult acute lymphoblastic leukaemia: analysis of 1170 adult ALL patients enrolled in the GIMEMA trials
Pagano, L., Annino, L., Ferrari, A., Camera, A., Martino, B., Montillo, M., Tosti, M. E., Mele, A., Pulsoni, A., Vegna, M. L., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00616.x · Cited by 17
Self-citation
Is family history of breast cancer a marker of susceptibility to exposures in the incidence of de novo adult acute leukemia?
Rauscher, G. H., Sandler, D. P., Poole, C., Pankow, J. S., Shore, D., Bloomfield, C. D., & Olshan, A. F. (2003) · PubMed · Cited by 16
Risk Stratification for Survival and Leukemic Transformation in Essential Thrombocythemia: A Single Institutional Study of 605 Patients.
Gangat, N., Wolanskyj, A. P., McClure, R. F., Li, C. Y., Schwager, S. M., Wu, W., & Tefferi, A. (2006) · Blood · doi:10.1182/blood.v108.11.3599.3599 · Cited by 9
Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 114 adult patients
Rund, D. G., Krichevsky, S., Cohen, S. B., Goldschmidt, N., Kedmi, M., Malik, E., Gural, A., Shafran‐Tikva, S., Ben‐Neriah, S., & Ben‐Yehuda, D. (2009) · Hematology Meeting Reports (formerly Haematologica Reports) · doi:10.4081/hmr.v2i15.610 · Cited by 5
Self-citation

Research works printed but not linked: 4

Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998;95:13176-81.
Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, et al. Acute myeloid leukemia in children treated with epipodophillotoxins for acute lymphocytic leukemia. N Engl J Med 2001;325,1682-7.
Cuzick J, Erskine S, Edelman D, Galton DA. A comparison of the inci- dence of the myelodisplasic syndrome and acute myeloid leukemia following melphalan and cyclophosphamide treatement for myelomatosis. Br J Cancer 1987;55:523-9.
Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagre- lide in high-risk essential thrombocy- themia. N Engl J Med 2005;353: 33-45.

Sorted by citations

Osteosarcoma
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., Arber, D. A., Bhatt, V. R., Bixby, D. L., Blum, W. G., Coutre, S. E., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0116 · Cited by 648
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Tallman, M. S., Wang, E. S., Altman, J. K., Appelbaum, F. R., Bhatt, V. R., Bixby, D. L., Coutre, S. E., Lima, M. J. G. D., Fathi, A. T., Fiorella, M., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0028 · Cited by 423
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
Takahashi, K., Wang, F., Kantarjian, H., Doss, D., Khanna, K., Thompson, E., Zhao, L., Patel, K., Neelapu, S., Gumbs, C., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30626-x · Cited by 399
Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction
Wood, M. E., Vogel, V. G., Ng, A. K., Foxhall, L. E., Goodwin, P. J., & Travis, L. B. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.8681 · Cited by 325

See all 236

Authors: Leone, G., Pagano, L., Ben-Yehuda, D., & Voso, M. T.
Affiliations: Università Cattolica del Sacro Cuore (IT)
Corresponding author: Leone, G.
ORCID: Leone, G.
Pagano, L.
Voso, M. T.
Venue: Haematologica
Publisher: Ferrata Storti Foundation (Haematologica)
Published: 2007-10-01
Volume: 92
Issue: 10
Pages: 1389-1398
ISSN: 0390-6078 (ISSN-L)
1592-8721
DOI: 10.3324/haematol.11034
OpenAlex: W2148305047
Cited by: 236
References: 73
Citations by year: 2026: 9 · 2025: 6 · 2024: 4 · 2023: 9 · 2022: 16 · 2021: 15 · 2020: 2 · 2019: 5 · 2018: 6 · 2017: 8 · 2016: 12 · 2015: 16 · 2014: 15 · 2013: 15 · 2012: 19
FWCI: 10.79
Type: journal article
Language: en
Open access: gold
doi.org
Locations: Haematologica (publishedVersion)
PubMed (publishedVersion)
Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Keywords: therapy-related myelodysplastic syndrome, therapy-related acute myeloid leukemia, secondary malignancies, alkylating agents, topoisomerase II inhibitors, azathioprine, DNA mismatch repair, 11q23 translocation, Hodgkin's disease, non-Hodgkin lymphoma, total body irradiation, autologous stem cell transplantation, granulocyte colony-stimulating factor, acute lymphoblastic leukemia, breast cancer, germ cell tumors, genetic susceptibility, polymorphism
MeSH terms: Animals, Disease Susceptibility, DNA, DNA Topoisomerases, Type II, DNA Repair, Humans, Leukemia, Myelodysplastic Syndromes, Polymorphism, Genetic, Radiotherapy, Risk Factors, Incidence, Topoisomerase II Inhibitors, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Therapy-related leukemia and myelodysplasia: susceptibility and incidence

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks